Foundery Innovations is an immunotherapy venture studio that partners with academic researchers to fund, de‑risk, and accelerate early‑stage drug discovery for autoimmune, inflammatory, infectious, and cancer diseases. Leveraging its AI‑driven Immune Archetype Platform, in‑house biologics expertise, and rapid “quick‑kill” experimental workflows, the studio creates pharma‑ready biologic candidate packages that can be spun out as biotech companies or licensed to pharmaceutical partners.
Funding
Funding not disclosed
Founders
Product
Problem
Academic discoveries in immunology often face high licensing costs, complex early‑development hurdles, and limited resources, preventing promising concepts from advancing to clinical testing for autoimmune, inflammatory, infectious, and cancer diseases.
Solution
Foundery Innovations operates as an immunotherapy venture studio that partners with university researchers to fund, de‑risk, and accelerate early‑stage drug discovery. The studio combines AI‑driven target identification, deep immune phenotyping (Immune Archetype Platform), and in‑house biologics expertise to generate Pharma‑ready candidate packages. By conducting rapid “quick‑kill” experiments and iterative validation, it efficiently converts novel concepts into advanced development candidates that can be spun out as biotech companies or licensed to pharmaceutical partners. The model leverages shared infrastructure, data‑driven decision making, and co‑ownership arrangements to streamline translation from academia to clinic.
Target Audience
Primary customers are academic immunology labs and senior scientists seeking partnership to advance their discoveries, as well as biopharmaceutical companies looking to license de‑risked immunotherapy candidates.
Features
- AI/ML‑based target discovery integrated with the proprietary Immune Archetype Platform for high‑resolution immune state profiling
- In‑house laboratory capabilities covering antibody engineering, protein science, in vitro and in vivo pharmacology, bioanalytics, and biomarker development
- Rapid “quick‑kill” experimental workflows to de‑risk candidates early and allocate capital efficiently
- Co‑development partnerships with academic investigators, providing research funding and shared economic returns
- Generation of Pharma‑ready biologic candidates (e.g., monoclonal antibodies and derivatives) ready for spin‑out or licensing
- Data‑driven prioritization and iterative validation pipeline to produce advanced development packages